Piper Sandler Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating, Maintains Target Price $20
Craig-Hallum Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating
Craig-Hallum Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating, Maintains Target Price $18
Oppenheimer Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating, Maintains Target Price $21
Scotiabank Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating, Maintains Target Price $20
Piper Sandler Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating, Maintains Target Price $20
Scotiabank Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating, Maintains Target Price $20
Craig-Hallum Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating, Maintains Target Price $18
Skye Bioscience Analyst Ratings
JMP Securities Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating, Maintains Target Price $15
Craig-Hallum Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating, Maintains Target Price $18
Oppenheimer Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating, Maintains Target Price $21
JMP Securities Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating, Maintains Target Price $15
Skye Bioscience Initiated at Market Outperform by JMP Securities
JMP Securities Initiates SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating, Announces Target Price $15
Piper Sandler Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating, Maintains Target Price $20
Cantor Fitzgerald Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating, Cuts Target Price to $14
Skye Bioscience Price Target Maintained With a $14.00/Share by Cantor Fitzgerald
Skye Bioscience Analyst Ratings
Craig-Hallum Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating, Announces Target Price $18